To view the PDF file, sign up for a MySharenet subscription.

SKJ - Sekunjalo Investments - Unaudited group interim results for the period

Release Date: 11/05/2010 16:45
Code(s): SKJ
Wrap Text

SKJ - Sekunjalo Investments - Unaudited group interim results for the period ended 28 february 2010 and cautionary announcement Sekunjalo Investments Limited (Incorporated in the Republic of South Africa) Registration number 1996/006093/06 Share code: SKJ and ISIN: ZAE000017893 ("Sekunjalo" or "the Group" or "the Company") Unaudited Group Interim results for the period ended 28 February 2010 and Cautionary announcement ABRIDGED GROUP STATEMENT OF COMPREHENSIVE INCOME Unaudited Unaudited Audited 28 February 28 February 31 August
2010 2009 2009 R`000 R`000 R`000 Revenue 183 533 167 972 405 910 Profit/(loss) from operations 14 185 -27 883 11 827 Investment revenue 7 927 4 411 5 649 (Loss)/income from associate 4 944 -3 365 -5 224 Finance Cost -15 945 -6 636 -18 786 Profit/(loss) before tax 11 111 6 237 -46 244 Tax -1 174 -2 579 -13 928 Profit / (Loss) after tax from 9 937 continuing operations 3 658 -60 172 Profit after tax from - discontinuing operations - 1 400 Other comprehensive income - - - Total comprehensive 9 937 income/(loss) 3 658 -58 772 Attributable To:- Outside shareholders 28 173 169 Parent 9 909 3 485 -58 941 Total comprehensive income / 9 937 (loss) 3 658 -58 772 Headline earnings 2 689 1 120 7 571 Number of shares in issue 489 339 (`000) 489 339 488 809 Weighted number of shares in 489 339 issue (`000) 489 339 489 073 Diluted number of shares in 489 339 issue (`000) 489 339 489 073 Headline Earnings per share 0.23 0.55 1.55 (cents) - continuing operations 0.23 0.55 1.26 - discontinuing operations - - 0.29 Earnings / (loss) per share 0.71 2.02 -12.05 (cents) - continuing operations 0.71 2.02 -12.34 - discontinuing operations - - 0.29 Diluted earnings per share 0.71 0.55 1.32 (cents) Net Asset Value per share 81.26 93.77 80.57 (cents) Tangible net asset value per 64.56 66.61 63.63 share (cents)
ABRIDGED GROUP STATEMENT OF FINANCIAL POSITION Unaudited Unaudited Audited
28 February 28 February 31 August 2010 2009 2009 R`000 R`000 R`000 ASSETS Non current assets 587 623 525 314 504 822 Property, Plant and Equipment 195 688 142 425 143 614
Goodwill 94 459 57 642 57 642 Intangibles 45 950 24 176 25 244
Other Investments - - - Investments in Joint Ventures - 50 50
Investments in Associates 154 994 155 766 144 776 Biological assets - - -
Other Financial Assets 63 326 113 264 102 164 Deferred tax 33 206 31 991 31 332
Current assets 263 280 185 183 200 249 Inventory 59 982 29 132 21 634 Biological assets 33 057 37 065 38 320 Other Financial Assets 3 740 11 001 22 066 Tax 993 1 155 451 Trade and other receivables 148 804 74 879 66 723 Bank 16 704 31 951 51 055
Assets of disposal groups - classified as held for sale - 18 386 TOTAL ASSETS 850 903 710 497 723 457 EQUITY AND LIABILITIES
Capital and reserves Share capital and share premium 402 977 403 177 402 977 Reserves 121 194 121 194 121 194 Accumulated losses -126 447 -58 513 -129 932 Equity Attributable to Parent 397 724 466 355 394 239 Outside shareholders interest -2 594 -7 478 -1 942 Total Equity 395 130 458 877 392 297 Non current liabilities 152 718 167 493 153 448 Other financial liabilities 56 002 81 555 57 019 Deferred tax 93 712 84 884 93 044 Other non-current liabilities 2 475 1 054 2 369 Loans from group companies 529 - 1 016 Current liabilities 162 649 224 533 165 971 Trade and other payables 68 728 119 779 59 372 Other Financial Liabilities 9 298 20 461 17 035 Other current liabilities 245 6 378 788 Provisions 15 968 3 800 23 571 Bank overdraft 49 179 57 062 43 587 Tax 19 231 17 053 21 618 Liabilities of disposal groups - - 11 741 classified as held for sale TOTAL EQUITY AND LIABILITIES 850 903 723 457 710 497
ABRIDGED GROUP STATEMENT OF CHANGES IN EQUITY Outside Total Attributable
To Equity Shareholders Parent interest R 000`s R 000`s R 000`s
Balance at 1 September 2008 455 949 -6 359 449 590 Loss/(profit) for the year -58 941 169 -58 772 Issue of preference shares in - 634 634 subsidiary Treasury shares -200 - -200 Dividends paid - -679 -679 Business combinations -2 569 4 293 1 724 Balance at 31 August 2009 394 239 -1 942 392 297 Net profit for the period 3 485 173 3 658 Dividends paid - -825 -825 Balance at 28 February 2010 397 724 -2 594 395 130 ABRIDGED GROUP STATEMENT OF CASH FLOWS Audited Unaudited Unaudited 28 28 31 August
February February 2009 2010 2009 R`000 R`000 R`000 CASH FLOW FROM OPERATING -14 770 -56 111 1 586 ACTIVITIES CASH FLOWS FROM INVESTING 10 730 -76 448 -22 749 ACTIVITIES CASH FLOWS FROM FINANCING -20 657 56 102 23 914 ACTIVITIES
(Decrease)/Increase in cash and -24 697 -76 457 2 751 cash equivalents Cash and cash equivalents at the 7 468 36 099 4 717 beginning of the period CASH EQUIVALENTS AT THE END OF -17 229 -40 358 7 468 THE PERIOD SEGMENTAL ANALYSIS Financial Informatics Fishing Healthcare Services Unaudited Unaudited Unaudited Unaudited 28 Feb 2010 28 Feb 2010 28 Feb 28 Feb
2010 2010 R`000 R`000 R`000 R`000 Revenue 8 928 50 553 78 574 5 749
Segment Result Operating -4 276 3 760 4 124 -4 196 profit/(loss)
Carrying amount of 24 425 42 306 267 591 36 348 Assets Carrying amount of 56 792 35 587 143 858 56 517 Liabilities Profit/(Loss) from - - - - equity accounted investments Biotechnology Corporate Group Unaudited Unaudited Unaudited
28 Feb 2010 28 Feb 2010 28 Feb 2010 R`000 R`000 R`000 Revenue - 24 168 167 972 Segment Result Operating - 13 12 428 11 827 profit/(loss) Carrying amount of 144 993 194 834 710 497 Assets Carrying amount of 7 351 15 260 315 365 Liabilities Profit/(Loss) from -3 365 - -3 365 equity accounted investments
Financial Informatics Fishing Healthcare Services Unaudited Unaudited Unaudited Unaudited 28 Feb 2009 28 Feb 2009 28 Feb 28 Feb
2009 2009 R`000 R`000 R`000 R`000 Revenue 5 432 71 182 65 954 6 817
Segment Result Operating 4 490 10 541 - 86 -3 015 profit/(loss)
Carrying amount of 33 862 59 427 409 127 72 734 Assets Carrying amount of 56 438 43 557 145 687 46 455 Liabilities Profit/(Loss) from - 6 599 - - equity accounted investments Biotechnology Corporate Group Unaudited Unaudited Unaudited
28 Feb 2009 28 Feb 2009 28 Feb 2009 R`000 R`000 R`000 Revenue - 34 148 183 533 Segment Result Operating - 23 2 278 14 185 profit/(loss) Carrying amount of 185 308 90 445 850 903 Assets Carrying amount of 49 223 50 666 392 026 Liabilities Profit/(Loss) from -1 655 - 4 944 equity accounted investments Note 1. Operating profits/(losses) are stated after elimination of management fees. Calculation of Headline Earnings Unaudited Unaudited Audited 28 28 31
February February August 2010 2009 2009 Notes R`000 R`000 R`000
Earnings/(loss) attributable IAS 33 3 485 9 909 -58 941 to ordinary equity holders of parent entity Adjusted for: Impairments of property, IAS 16/IAS - - 31 675 plant and equipment 36 Impairments of intangible IAS 38/IAS - - 18 713 assets 36 Gains on disposal of IAS 36 i -2 365 -2 302 -1 935 property, plant and equipment Gains on disposal of IFRS3 - -4 918 1 429 subsidiaries Impairment of goodwill IFRS3 - - 3 425 Impairments of other IAS36 - - 13 205 financial instruments Headline earnings 1 120 2 689 7 571 Notes: This profit arose from the disposal of the Head office building in Tokai, Cape Town as a result of restructuring within group. Additional financial information: Included in the income statement is R12,75m of fair valuation adjustments to the Group`s investments. Refer to segment report for fair valuations within each division. The Group is carrying its investment in associate, namely, Bioclones (Pty) Ltd, at cost because of the complexities and subjectivity involved in determining a fair value for the business. Basis of preparation of financial statements The abridged consolidated financial information has been prepared in accordance with IAS 34 - Interim financial reporting and is based on the unaudited financial statements of the Group for the six months ended 28 February 2010, which have been prepared in accordance with International Financial Reporting Standards ("IFRS"), the Listings Requirements of the JSE Limited, and the Companies Act of South Africa, as amended. The unaudited financial results for the six months ended 28 February 2010 have been prepared in accordance with the Group accounting policies, which comply with IFRS and are consistent with those applied in the previous financial period. OVERVIEW CORPORATE PROFILE Sekunjalo is a black controlled investment holding company incorporated in the Republic of South Africa and is listed on the JSE Limited ("JSE"). The Group has investments in the following sectors: Fishing, Aquaculture, Information Communication Technology; Pharmaceuticals and Biotechnology. EMPOWERMENT PARTNER OF CHOICE Sekunjalo is: ranked as South Africa`s Top Empowered Company for 2010 by the authoritative Financial Mail/Empowerdex Top Companies Awards; KEY FINANCIAL HIGHLIGHTS The results are in line with expectations set to bring all operations to a strengthened position. The process of restructuring has been successfully completed. The major changes to note are summarised as follows: The total liabilities for the Group have decreased by 28% to reflect better debt management; The financing cost of debt has also declined in line with our strategy; and The net cash effect of the Group has positively increased by R23 million. The Group is currently showing the expected signs of recovery with a profit of R3,6 million for the period under review despite the impact of the global economic crisis on the local and export markets. Reporting revenue is down compared to the prior period due to the disposal of one of the IT businesses as well as the impact of the stronger rand on exports in the fishing sector. The Group is satisfied that the Fishing, Aquaculture, ICT and pharmaceutical businesses are showing satisfactory performances for the interim period. The Group is confident that the strategic initiatives implemented by the divisions are in line to overcome their current positions. The Group`s net asset value has improved since the last financial year-end. REVIEW OF INVESTMENTS FISHING Premier Fishing SA (Pty) Ltd ("Premier Fishing") has performed satisfactorily despite the effects of the stronger rand on sales and the depressed international prices due to the global economic slowdown. The restructuring process of Premier Fishing has successfully been completed and a strong dynamic management team is in place. Interim results show Premier Fishing making an operating profit of R4,1 million in comparison to its breakeven results in the previous interim period. The West Coast Rock Lobster`s catches have improved from the comparative period. However, this has been negatively impacted by the stronger rand. Catches are expected to further improve, which will enhance the division`s performance in the short to medium term. Sales are expanding into the Far Eastern markets. The South Coast Rock Lobster division has performed well and has seen prices in US dollar terms improve after a significant drop in the aftermath of the global financial crisis. This has been negatively impacted by the stronger rand. Demand is still strong and greater efficiency on the distribution is expected after improved terms where negotiated with international distributors. The pelagic division is still facing challenges and is in the process of being restructured. Further investment into this sector in partnership with other enterprises is being planned. This will strategically position the division for growth in the medium to long term. The squid catches have been in line with expectations but selling prices have been under significant pressure and have been negatively affected by the stronger rand. Premier Fishing is well positioned to take advantage of future growth opportunities due to its strong empowerment credentials and low gearing. Management is continually looking for new opportunities to expand their fishing portfolio and maintain good relations with various industry stakeholders. AQUACULTURE The Group`s strategy to previously invest in the abalone division continues to deliver sustainable earnings year on year and exceeded its sales volume for the six months under review. However, the stronger rand has affected the division`s earnings. The abalone farm in Gansbaai is now at operating at greater capacity and is capable of satisfying demand for the Asian markets. Seagro, the organic fertiliser, continues to have a strong market presence and performance. The division is now reaping the benefits of economies of scale after consolidating all its operations into the Gansbaai operation. The demand for the highly sought after commodity still remains high from the Eastern markets. Management is continually pursuing opportunities to expand on the current operations. INFORMATION COMMUNICATION TECHNOLOGY Sekunjalo Technology Solutions Group Limited (Pty) Ltd ("Sekunjalo TSG") is a wholly owned subsidiary of Sekunjalo and focuses on acquiring and growing niche-market technology companies. Sekunjalo TSG continues to perform well, with subsidiaries that are cash positive and has strong statements of financial position. The Group has performed well despite the failure of the Gauteng Department of Health ("GDOH") to honour its obligations in its contract with Amethst (Pty) Ltd ("Amethst"). Revenue is well ahead of targets for the period under review. The decline in revenue in comparison with the previous period is mainly due to the sale of one the subsidiary companies through a management buy-out and the cancelation of the GDOH`s contract. The total debt in the Sekunjalo TSG Group has decreased by 34%, indicating that the debt management within the Sekunjalo TSG Group has improved as well as the Group`s ability to fund its own operations. Total assets in the Group have decreased by 29%, due to the buy-out in the preceding year. The Sekunjalo TSG Group maintains a strong statement of its financial position. FIOS (Pty) Ltd, is a leading provider of corporate performance management solutions offering both business intelligence and financial solutions and continues to perform well despite the initial slow start to the period. Saratoga Software (Pty) Ltd, a software development company that builds custom software solutions for corporate customers, has built on their previous successes and has been awarded additional medium-term contracts, despite various clients being faced with severe budget cuts. Saratoga is operating well above targets. Digital Matter (Pty) Ltd, is an innovative technology company providing software solutions for a wide range of industry applications. As a Gold Certified Microsoft Partner in Mobility Competencies, they utilise the full range of the latest Microsoft technologies in products and solutions. Digital Matter has exceeded expectations with revenues increasing by 40%. Acquired in March 2009, Digital Matter has proven itself in the market by acquiring significant contracts with reputable clients. Health System Technologies (Pty) Ltd ("HST"), a Hospital Information System ("HIS") provider, continues to rollout HIS to the Provincial Government hospitals. The business has consistently performed well over the past few years, with the exception of Amethyst due to the cancellation of the contract with GDOH, which resulted in a decrease in sales of 33% resulting in an operating loss of R1.2millon. Management has implemented a strategic plan where it is anticipated that HST will meet its targets by year-end. British Telecom Communication Services South Africa ("BT") one of the world`s leading providers of communication solutions and services operating in 170 countries, continues to perform well, despite the economic climate. Its principal activities includes the provision of networked IT services globally; local, national and international telecommunications services to customers for use at home, work and on the move; broadband and internet products and services; and converged fixed/mobile products and services. The value of our investment has increased by 12% in comparison to the previous reporting period. It is well positioned to grow aggressively over the next few years. PHARMACEUTICALS The Health Care Division continues to show increased efforts with the strong management team and good portfolio of products by securing its supply chain, throughput and driving the implementation of its sale strategy. In the current year the Group commenced the launching of consumer products to pharmaceutical retail outlets. The first product of this range was successfully launched in March. The Group has also been awarded a public tender on its ethical products. Management has pursued opportunities to expand its current portfolio which will provide a better platform for future growth. BIOTECHNOLOGY Bioclones (Pty) Ltd ("Bioclones") has 22 global patents in the areas of novel technologies, infectious disease and cancer treatment molecules. The manufacturing cell culture facility in Pretoria is continuing its development to increase production at this facility. Bioclones is seeing improved uptake in both the private and state sectors due to the competitive price of the locally manufactured product, RepotinRegistered. Bioclones continues to prepare for the company`s listing of the company on an international stock exchange subject to market conditions. Investor appetite is slowly improving abroad, however market conditions are not yet optimal and the company is carefully monitoring the economic conditions to ensure the most favourable valuation associated with the listing of Bioclones. FUTURE PROSPECTS Sekunjalo is firmly established as the pre- eminent black empowerment group continuously looking for strategic opportunities. With low gearing the Group is well positioned to fund future growth of its businesses and to unlock value in its underlying investments. The Aquaculture division is properly resourced to take advantage of the expansion in the Far Eastern markets. The restructure of the pelagic division within the Fishing business will revitalise the pelagic sector. The strong recovery in the dermatological and pharmaceutical division will start reaping the rewards going forward. The continuous investment in our employees, the community and our sustainability programmes has enabled the Group to actively be involved in improving the economy of the country. Sekunjalo has strong B-BBEE credentials and has become a partner of choice to multinationals. Our World Economic Forum Global status provides a network platform with the international business community which brings strategic partners and opportunities for the Group. Dividends No dividends have been declared for the current period. The Board continues to work towards payment of dividends in the foreseeable future. APPRECIATION We wish to extend my sincere gratitude to our Board of Directors, the Group Executives, the management and staff within the Group for their loyalty, dedication and unselfish commitment in meeting the business challenges of the past six months. Our appreciation also goes to our business partners for their support during this period. CAUTIONARY ANNOUNCEMENT Shareholders are advised that Sekunjalo has entered into negotiations with a third party, which, if successfully concluded may have a material effect on the price of the company`s securities. Accordingly, shareholders are advised to exercise caution when dealing in the company`s securities until a full announcement is made. MI Surve K Abdulla Executive chairman Chief executive officer Cape Town 11 May 2010 Directors *Dr M Iqbal Surve (Executive Chairman); *Khalid Abdulla; Reverend Vukile Mehana, Mihe Gaomab, The First; Salim Young; *Cherie Felicity Hendricks; *Chantelle Ah Sing *Executive Directors Company secretary: Cherie Felicity Hendricks Registered Address: Quay 7, East Pier, Victoria and Alfred Waterfront, Cape Town, 8001, email: cherieh@sekunjalo.com Transfer secretaries: Link Market Services South Africa (Pty) Ltd, 11 Diagonal Street, Johannesburg Sponsor: PSG Capital (Pty) Ltd, Stellenbosch Date: 11/05/2010 16:45:01 Supplied by www.sharenet.co.za Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.

Share This Story